RTW Investments’s Gyre Therapeutics GYRE Stock Holding History

RTW Investments’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-3,385	Closed	-$1.77M	–	42
2015 Q3	$1.77M	Hold	3,385	–	–	0.55%	26
2015 Q2	$7.44M	Hold	3,385	–	–	2.16%	14
2015 Q1	$7.92M	Hold	3,385	–	–	3.57%	10
2014 Q4	$7.01M	Buy	+3,385	New	+$6.52M	2.59%	13

Other funds holding GYRE

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CCM

Colorado Capital Management Boulder, Colorado $293M AUM 22.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments's GYRE Position: Q4 2015 in Review

RTW Investments sold out of Gyre Therapeutics (GYRE) in Q4 2015, closing a stake of 3,385 shares — an estimated $1.77M sold.

RTW Investments first reported a position in GYRE in Q4 2014 and held it in 4 quarters. The position peaked at $7.92M in Q1 2015. 35 funds tracked by Wall St. Rank hold GYRE as of Q4 2015.

RTW Investments reported no remaining Gyre Therapeutics position as of Q4 2015 after selling out during the quarter.
RTW Investments sold 3,385 Gyre Therapeutics shares in Q4 2015, an estimated $1.77M.
RTW Investments first reported a position in Gyre Therapeutics in Q4 2014 and held it in 4 quarters.
RTW Investments's Gyre Therapeutics position peaked at $7.92M in Q1 2015.
35 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2015.

Based on RTW Investments's 13F filing for Q4 2015, filed 16 Feb 2016.